Name: A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum (Video) | JoVE Journal
Uploaded: 2018-04-10T14:00:00.000+00:00
Duration: 7 min 6 s
Description: Learn a flow cytometry assay to measure antibody dependent enhancement of dengue virus using Zika virus convalescent serum. This high-throughput method assesses cross-reactive antibody effects in vitro.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

The described project was supported by funds from the Uniformed Services University of the Health Sciences to JJM. The opinions or assertions contained herein are the private ones of the authors and are not to be construed as official or reflecting the views of the Department of Defense, the Uniformed Services University of the Health Sciences or any other agency of the U.S. Government.
WGV performed all the experiments and analyzed the data; JJM designed and supervised the study; WGW and JJM wrote the paper.

The serum samples used to demonstrate the protocol described here were obtained from rhesus macaques that were housed and cared for in accordance with local, state and federal policies in an Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC)-accredited facility. All animal experiments were reviewed and approved by Institutional Animal Care and Use Committee and samples were acquired through a tissue sharing protocol.
1. Day 1
NOTE: Perform all the steps described below in a sterile laminar flow biosafety cabinet used for tissue culture in a BSL-2 laboratory.
<ol>
	<li>Thaw the serum samples at room temperature and transfer 100 &#181;L of each serum sample to a sterile tube. Heat inactivate for 30 min at 56&#176;C either in a water bath or a temperature-adjustable thermomixer. Make 10-fold serial dilutions of the serum sample ranging from 1:1 to 1:1,000 using cold RPMI-10 (RPMI with 10% fetal bovine serum).</li>
	<li>Transfer 10 &#181;L of serially diluted serum sample to each well of a sterile 96-well V-bottom plate. Include two sets of control wells, RPMI-10 with RVPs only and without serum sample, and RPMI-10 only without RVPs and without serum sample. Set up each serum sample and RPMI-10 controls in triplicates.</li>
	<li>Remove the Dengue-1, 2, 3 and 4 RVPs from the -80 &#176;C freezer and thaw them in a 37 &#176;C water bath. Transfer the thawed RVPs immediately to ice. Obtain approximately 170 &#181;L RVPs for each serum sample (10 &#181;L of RVPs x 3 wells for each serum dilution (1:1, 1:10, 1:100, 1:1,000) and 10 &#181;L of RVPs x 3 wells for each of the RPMI-10 with RVP only control wells).</li>
	<li>Pipette 10 &#181;L of RVPs into each well of the 96-well V-bottom plate containing the serum sample and to the RPMI-10 with RVPs (no serum) control wells. Do not add RVPs to the RPMI-10 only (no serum sample and no RVP) wells. Mix thoroughly by pipetting up and down 5&#8211;10 times. Add 10 &#181;L cold RPMI-10 in lieu of RVPs to each cold RPMI-10 only (no serum sample and no RVP) control wells.</li>
	<li>Transfer the 96-well V-bottom plate to an incubator and incubate the plate for 1 hour at 37 &#176;C in the presence of 5% CO2. While the 96-well V-bottom plate is incubating, clean the surface of the biosafety cabinet with 70% ethanol and run the UV light for 15 min.</li>
	<li>Remove a fully confluent T75 flask of K562 cells from the incubator, mix the cells well using a sterile 5 mL pipet, and transfer 5 mL of cells to a sterile 15 mL conical tube. 
	NOTE: The K562 cells are maintained in RPMI-10 and subcultured at 1 x 106/mL.</li>
	<li>Count the number of cells by removing 10 &#181;L cells from the sterile 15 mL conical tube and mix with 10 &#181;L tryphan blue. Count the cells using a hemocytometer to determine the total number of cells in the 15 mL conical tube.</li>
	<li>Centrifuge the 15 mL conical with cells at ~1,200 x g for 10 minutes, decant the supernatant, and resuspend the cells in warm RPMI-10 at a concentration of 80,000 cells/30 &#181;L of media (2.66 x 106 cells /mL).</li>
	<li>Remove the 96-well V-bottom plate from the incubator (step 1.6), transfer 30 &#181;L of K562 cells to each well of the 96-well V-bottom plate, and mix thoroughly by pipetting up and down 5&#8211;10 times. Transfer the 96-well V-bottom plate to an incubator and incubate the plate for 1 hr at 37 &#176;C in the presence of 5% CO2.</li>
	<li>After incubating for 1 h, remove the 96-well V-bottom plate from the incubator and centrifuge at ~1,200 x g for 5 minutes. After centrifugation, decant the media from the wells by turning the plate upside down into a container containing 10% bleach.</li>
	<li>Wash the cells in each well by resuspending them in 125 &#181;L of warm RPMI-10, mix thoroughly with a pipette, and centrifuge the plate at ~1,200 x g for 5 min. Decant the media by turning the plate upside down into a container containing 10% bleach. Repeat this wash step two times.</li>
	<li>After washing, add 100 &#181;L of warm RPMI-10 to each well, mix up and down with the pipet, and incubate the plate for 48 h at 37 &#176;C in the presence of 5% CO2.</li>
</ol>
2. Day 3
<ol>
	<li>Remove the 96-well V-bottom plate containing 100 &#181;L of cells and media/well from the incubator and move it to a biosafety cabinet . Using a multichannel pipette, mix the contents of each well and transfer the cells and media to a 96 well U-bottom plate or to pre-labeled 5 mL polypropylene tubes.</li>
	<li>Rinse each well in the 96-well V-bottom plate with 100 &#181;L of 1% Paraformaldehyde (PFA) in 1x Phosphate Buffered Saline (PBS) and transfer to the respective wells in the 96 well U-bottom plate or labeled 5 mL polypropylene tubes from step 2.1 to yield a final concentration of 0.5% PFA/well or tube. Mix thoroughly using a multichannel pipette, cover the plate with aluminum foil, and let it sit in the incubator for 30 minutes to fix the cells.</li>
	<li>Prepare the flow cytometer (see Table of Materials for example) by running unstained K562 cells to calibrate the side and forward scatter along with the fluorescence settings. The only fluorescence channel required is FL1, as GFP is the only fluorescence emitted from the cells. Acquire ~30,000&#8211;50,000 cells from each sample. 
	NOTE: Any flow cytometer capable of reading a single fluorescence can be used for acquiring the data, as cells infected with RVPs will only emit green fluorescence due to the presence of GFP, and no other fluorescence channel are needed.</li>
</ol>
3. Data Analysis
<ol>
	<li>Analyze data acquired on the flow cytometer using any flow cytometry analysis software (see Table of Materials).
	<ol>
		<li>Set the first gate based on FSC-A (forward scatter &#8211; area) vs FSC-H (forward scatter &#8211; height) to include single cells and exclude auto-fluorescent doublets from analysis12. Then, gate singlet-gated cells based on SSC-A (side scatter &#8211; area) vs FSC-A to exclude any autofluorescent debris.</li>
		<li>Analyze SSC-A vs FSC-A gated cells for the expression of GFP based on SSC-A vs GFP-A. Determine the percentage of GFP+ cells for each dilution of the serum and control samples by setting a gate around GFP+ cells.</li>
	</ol>
	</li>
	<li>Determine the average percentage of GFP+ cells for each serum sample dilution and control wells by dividing the total percentage of GFP+ cells in the triplicate wells by 3.</li>
	<li>Calculate fold-enhancement of infection by dividing the average percentage of GFP+ cells in the serum samples for each dilution divided by the average percentage of GFP+ cells in the RPMI-10 with RVPs (no serum sample) control wells.</li>
	<li>Graph fold-enhancement (y-axis) versus dilution (x-axis), and perform statistical analysis using ANOVA followed by Tukey&#39;s post-hoc test for multiple comparisons.</li>
</ol>

<ol><li>George, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Prior+exposure+to+zika+virus+significantly+enhances+peak+dengue-2+viremia+in+rhesus+macaques%5BTitle%5D)+AND+%22Sci+Rep%22%5BJournal%5D)">Prior exposure to zika virus significantly enhances peak dengue-2 viremia in rhesus macaques.</a> Sci Rep. 7 (1), 10498(2017).</li>
<li>Stettler, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Specificity%2C+cross-reactivity%2C+and+function+of+antibodies+elicited+by+Zika+virus+infection%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection.</a> Science. 353 (6301), 823-826 (2016).</li>
<li>Mattia, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Dengue+reporter+virus+particles+for+measuring+neutralizing+antibodies+against+each+of+the+four+dengue+serotypes%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes.</a> PLoS One. 6 (11), e27252(2011).</li>
<li>Chiofalo, M. S., Teti, G., Goust, J. M., Trifiletti, R., La Via,, F, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Subclass+specificity+of+the+Fc+receptor+for+human+IgG+on+K562%5BTitle%5D)+AND+%22Cell+Immunol%22%5BJournal%5D)">Subclass specificity of the Fc receptor for human IgG on K562.</a> Cell Immunol. 114 (2), 272-281 (1988).</li>
<li>Klein, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Properties+of+the+K562+cell+line%2C+derived+from+a+patient+with+chronic+myeloid+leukemia%5BTitle%5D)+AND+%22Int+J+Cancer%22%5BJournal%5D)">Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia.</a> Int J Cancer. 18 (4), 421-431 (1976).</li>
<li>Kliks, S. C., Nisalak, A., Brandt, W. E., Wahl, L., Burke, D. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Antibody-dependent+enhancement+of+dengue+virus+growth+in+human+monocytes+as+a+risk+factor+for+dengue+hemorrhagic+fever%5BTitle%5D)+AND+%22Am+J+Trop+Med+Hyg%22%5BJournal%5D)">Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever.</a> Am J Trop Med Hyg. 40 (4), 444-451 (1989).</li>
<li>Littaua, R., Kurane, I., Ennis, F. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Human+IgG+Fc+receptor+II+mediates+antibody-dependent+enhancement+of+dengue+virus+infection%5BTitle%5D)+AND+%22J+Immunol%22%5BJournal%5D)">Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection.</a> J Immunol. 144 (8), 3183-3186 (1990).</li>
<li>Wang, T. T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((IgG+antibodies+to+dengue+enhanced+for+FcgammaRIIIA+binding+determine+disease+severity%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">IgG antibodies to dengue enhanced for FcgammaRIIIA binding determine disease severity.</a> Science. 355 (6323), 395-398 (2017).</li>
<li>Dejnirattisai, W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cross-reacting+antibodies+enhance+dengue+virus+infection+in+humans%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Cross-reacting antibodies enhance dengue virus infection in humans.</a> Science. 328 (5979), 745-748 (2010).</li>
<li>Kawiecki, A. B., Christofferson, R. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Zika+virus-induced+antibody+response+enhances+dengue+virus+serotype+2+replication+in+vitro%5BTitle%5D)+AND+%22J+Infect+Dis%22%5BJournal%5D)">Zika virus-induced antibody response enhances dengue virus serotype 2 replication in vitro.</a> J Infect Dis. 214 (9), 1357-1360 (2016).</li>
<li>Morens, D. M., Halstead, S. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Measurement+of+antibody-dependent+infection+enhancement+of+four+dengue+virus+serotypes+by+monoclonal+and+polyclonal+antibodies%5BTitle%5D)+AND+%22J+Gen+Virol%22%5BJournal%5D)">Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies.</a> J Gen Virol. 71 (Pt 12), 2909-2914 (1990).</li>
<li>Perfetto, S. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Amine+reactive+dyes%3A+an+effective+tool+to+discriminate+live+and+dead+cells+in+polychromatic+flow+cytometry%5BTitle%5D)+AND+%22J+Immunol+Methods%22%5BJournal%5D)">Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry.</a> J Immunol Methods. 313 (1-2), 199-208 (2006).</li>
<li>Priyamvada, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((B+Cell+responses+during+secondary+dengue+virus+infection+are+dominated+by+highly+cross-reactive%2C+memory-derived+plasmablasts%5BTitle%5D)+AND+%22J+Virol%22%5BJournal%5D)">B Cell responses during secondary dengue virus infection are dominated by highly cross-reactive, memory-derived plasmablasts.</a> J Virol. 90 (12), 5574-5585 (2016).</li>
<li>Priyamvada, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Human+antibody+responses+after+dengue+virus+infection+are+highly+cross-reactive+to+Zika+virus%5BTitle%5D)+AND+%22Proc+Natl+Acad+Sci+U+S+A%22%5BJournal%5D)">Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus.</a> Proc Natl Acad Sci U S A. 113 (28), 7852-7857 (2016).</li>
</ol>

The authors have nothing to disclose.

Flaviviruses such as DENV and ZIKV share significant evidence of homology in both their structural and non-structural proteins that generate antibodies that cross-react with each other13,14. These cross-reactive antibody responses have been shown to enhance of infection both in vivo and in vitro with either a heterologous serotype or other related flaviviruses1,2. The potential to cross ...

Antibody dependent enhancement (ADE) of infection is a process whereby partially cross-reactive antibody responses induced by a serotype of virus enhances uptake of another serotype of virus, leading to increased viral replication and viremia. ADE has been extensively documented in Dengue virus (DENV) infections where four major serotypes are prevalent. In a subset of patients, ADE is associated with Dengue hemorrhagic fever (DHF). We have recently shown that Zika virus (ZIKV) infection induced significantly high levels of DENV cross-reactive antibody responses that caused ADE of DENV in vitro and likely contributed to the enhancement of DENV viremia in vivo1,2. Antibody dependent enhancement assays are a valuable tool to assess the capacity of antibodies to enhance secondary infection with related viruses and provide valuable insights into the pathogenesis of flavivirus infections and inform the development of vaccines.
The assay described here uses DENV RVPs along with K562 cells that are normally impermissible to infection. RVPs are structurally intact replication incompetent DENV viral particles that encode a sub-genomic green fluorescent protein (GFP) replicon that is expressed after a single round of replication3. As such, cells that become infected with RVPs fluoresce green and can be readily detected using flow cytometry or microscopy. The RVPs used in this assay were obtained from commercial sources. They can, however, be generated against other viruses and used in the assay described in this manuscript. Meanwhile, K562 cells are an Fc&#947;III-receptor-expressing leukemia cell line that bind to the Fc region of antibodies and become infected in the presence of sub-neutralizing concentrations of antibody4,5.
ADE assays have been extensively used in studies investigating the risk factors for severe dengue and to delineate the mechanisms of in vitro ADE6,7,8.The ADE assay described here can be quickly and easily used to determine the capacity of serum to enhance in vitro infection using RVPs and flow cytometry, as compared to other assays used currently, which require either the determination of plaque forming units (pfu) in Vero cells or antibody staining of infected cells6,7,8,9,10,11, both of which are time consuming and labor intensive.

<table><tbody><tr><td>DENV 1-4 RVP</td><td>Integral Molecular</td><td>RVP-501</td><td></td></tr><tr><td>K562 cells</td><td>ATCC</td><td>CCL-243</td><td></td></tr><tr><td>RPMI</td><td>Corning</td><td>10-040-CV</td><td></td></tr><tr><td>FBS</td><td>GE lifesceinces</td><td>SH 30910.03</td><td>10% FBS in RPMI-10</td></tr><tr><td>Penicillin-Streptomycin</td><td>MP biomedicals</td><td>1670049</td><td>100 IU Pen/mL, 100 ug Strep/mL in RPMI-10</td></tr><tr><td>HEPES</td><td>Cellegro</td><td>25-060-Cl</td><td>0.025M in RPMI-10</td></tr><tr><td>MEM Non-essential Amino Acid Solution (100&amp;times;)</td><td>Sigma</td><td>M7145</td><td>1x in RPMI-10</td></tr><tr><td>Sodium Pyruvate</td><td>Cellegro</td><td>25-000-Cl</td><td>1mM in RPMI-10</td></tr><tr><td>L-glutamine</td><td>Fisher Scientific</td><td>MT25005CI&amp;nbsp;</td><td></td></tr><tr><td>Sterile V-bottom plates</td><td>Thomas Scientific</td><td>333-8001-01V</td><td></td></tr><tr><td>BD Falcon Polypropylene 5 ml FACS tubes</td><td>VWR</td><td>60819-728</td><td></td></tr><tr><td>Non-sterile U-bottom plates</td><td>Falcon</td><td>Ref 353910</td><td>A high throughput alternative to FACS tubes</td></tr><tr><td>5mL, sterile, serological pipette</td><td>Denville</td><td>P7127</td><td></td></tr><tr><td>200uL sterile pipette tips</td><td>Denville</td><td>P3020 CPS</td><td></td></tr><tr><td>20uL sterile pipette tips</td><td>Denville</td><td>P1121</td><td></td></tr><tr><td>50-200uL multichannel pipette</td><td>Denville</td><td>P3975-8-B</td><td></td></tr><tr><td>5-50uL multichannel pipette</td><td>Denville</td><td>P3975-9-B</td><td></td></tr><tr><td>20% formadehyde</td><td>Tousimis</td><td>&amp;nbsp;#1008B</td><td></td></tr><tr><td>Water Bath</td><td>ThermoFisher</td><td>TSCOL35</td><td></td></tr><tr><td>thermomixer</td><td>Eppendorf</td><td>2231000387</td><td>An alternative to a waterbath for heat inactivation</td></tr><tr><td>CO2 Incubator</td><td>ThermoFisher</td><td>13-998-213</td><td></td></tr><tr><td>Ethanol</td><td>Sigma Aldrich</td><td>E7023</td><td></td></tr><tr><td>Liquid Bleach</td><td>Fisher Scientific</td><td>NC9724348</td><td></td></tr><tr><td>Flowjo 9.8</td><td>TreeStar, Inc.</td><td></td><td>Flow cytometry analysis software</td></tr><tr><td>BD FACSDiva 6.1.2</td><td>Becton Dikinson</td><td></td><td></td></tr><tr><td>BD LSR II flow cytometer</td><td>Becton Dikinson</td><td></td><td></td></tr><tr><td>Liquid Bleach</td><td>Fisher Scientific</td><td>NC9724348</td><td></td></tr></tbody></table>

a simple flow cytometry based assay to determine in vitro antibody dependent enhancement of dengue virus using zika virus convalescent serum

A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum

Antibody dependent enhancement of infection has been shown to play a major role in Dengue viral pathogenesis. Traditional assays that measure the capacity of antibodies or serum to enhance infection in impermissible cell lines have relied on using viral output in the media followed by plaque assays to quantify infection. More recently, these assays have examined Dengue virus (DENV) infection in the cell lines using fluorescently labeled antibodies. Both these approaches have limitations that restrict the widespread use of these techniques. Here, we describe a simple in vitro assay using Dengue virus reporter viral particles (RVPs) that express green fluorescent protein and K562 cells to examine antibody dependent enhancement (ADE) of DENV infection using serum that was obtained from rhesus macaques 16 weeks after infection with Zika virus (ZIKV). This technique is reliable, involves minimal manipulation of cells, does not involve the use of live replication competent virus, and can be performed in a high throughput format to get a quantitative readout using flow cytometry. Additionally, this assay can be easily adapted to examine antibody dependent enhancement (ADE) of other flavivirus infections such as Yellow Fever virus (YFV), Japanese Equine Encephalitis virus (JEEV), West Nile virus (WNV) etc. where RVPs are available. The ease of setting up the assay, analyzing the data, and interpreting results makes it highly amenable to most laboratory settings.

Sera from 4 rhesus macaques were collected 16 weeks after infection with ZIKV and tested for their potential to enhance DENV-1, 2, 3 and 4 infection in K562 cells. The animals had peak viremia of ~1 x 105 copies of ZIKV RNA/mL of plasma by day 3 after infection that declined to levels that were below the limit of detection by 7 days after infection. No viremia was detected in the plasma at 16 weeks post-infection. Then, the RVP assay was performed and the collected data were an...

We describe a simple and easy protocol for measuring antibody dependent enhancement of infection by Zika virus convalescent serum using Dengue virus Reporter Viral Particles.

Antibody dependent enhancement of infection has been shown to play a major role in Dengue viral pathogenesis. Traditional assays that measure the capacity ...

a-simple-flow-cytometry-based-assay-to-determine-vitro-antibody

Research

JoVE Journal

Immunology and Infection

Source: Asad, S., et al. Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells. J. Vis. Exp. (2019)This video demonstrates antibody-dependent enhancement of Zika virus infection in human primary macrophages, using dengue antibody–virus complexes to model how cross-reactive antibodies facilitate Fcγ receptor–mediated viral entry and replication for studying infection mechanisms and immune interactions.

Antibody-Dependent Enhancement of Zika Virus by Dengue Antibodies in Human Primary Macrophages

This video demonstrates an assay to measure antibody-dependent enhancement (ADE) of Dengue virus infection using Zika Virus Convalescent Serum. The assay uses Dengue reporter viral particles (RVPs) encoding a green fluorescent protein. Serum antibodies against the Zika Virus cross-react with RVPs to form a complex. The bound antibodies enhance RVP uptake by cells expressing the Fc receptor, which is detected using flow cytometry.

An In Vitro Assay to Examine the Antibody-Dependent Enhancement of Viral Infection

The video demonstrates an in vitro assay for screening interferons with antiviral activity against the Zika virus, a human pathogen. Within the host cell, the Zika virus undergoes multiplication upon internalization, infecting neighboring cells and creating distinct zones or viral plaques. Type I interferon, acting as an antiviral agent, hinders virus multiplication, thereby preventing the formation of viral plaques in the host cell monolayer.

An In Vitro Assay for Screening Interferons as Potent Inhibitors of Zika Virus Growth

Zika Virus (ZIKV), an emerging pathogen, is linked to fetal developmental abnormalities and microcephaly. The establishment of an effective infectious cell culture system is crucial for studies of ZIKV replication as well as vaccine and drug development. In this study, various virological assays pertaining to ZIKV are illustrated and discussed.

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Viruses or extracellular vesicles were immunocaptured with 15 nm magnetic nanoparticles coupled to antibodies recognizing surface antigens. The captured virions or vesicles were labeled with fluorescent antibodies against other surface antigens. The resultant complexes were separated in high magnetic field and analyzed with conventional flow cytometers triggered on fluorescence.

Flow Virometry to Analyze Antigenic Spectra of Virions and Extracellular Vesicles

Current multiplexed diagnostics to detect Zika, chikungunya, and dengue viruses require complex sample preparation and expensive instrumentation, and are difficult to use in low resource environments. We show a diagnostic that uses isothermal amplification with target-specific strand displaceable probes to detect and differentiate these viruses with high sensitivity and specificity.

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

A protocol to evaluate antigen-specific T-cell responses in the immunoprivileged organs of the Ifnar1-/- murine model for the Zika virus (ZIKV) infection is described. This method is pivotal for investigating the cellular mechanisms of the protection and immunopathogenesis of ZIKV vaccines and is also valuable for their efficacy evaluation.

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

We describe a method to evaluate the effect of pre-existing immunity against dengue virus on the Zika virus infection by using human serum, primary human cells, and infection quantification by quantitative real-time polymerase chain reaction.

Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells

The present protocol describes the propagation of Zika virus (ZIKV) in Vero African green monkey kidney cells and the quantification of ZIKV using cell-based colorimetric immunodetection methods in 24-well and 96-well (high throughput) formats.

Virus Propagation and Cell-Based Colorimetric Quantification

Here, we demonstrate the use of cell-based electrical impedance (CEI) as a very easy and straightforward method to study Zika virus infection and replication in human cells in real time. Furthermore, the CEI assay is useful for the evaluation of antiviral compounds.

Cell-Based Electrical Impedance Platform to Evaluate Zika Virus Inhibitors in Real Time

Learn a flow cytometry assay to measure antibody dependent enhancement of dengue virus using Zika virus convalescent serum. This high-throughput method assesses cross-reactive antibody effects in vitro.

A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum (Video) | JoVE Journal

A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum

Explore More Videos